Prophase Labs (NasdaqCM:PRPH) 2025 Conference October 30, 2025 11:00 AM ET Speaker1Thank you for being here. It's my pleasure to introduce our next speaker. My name is Dale Jones. I'm with Sales Consulting. We are an accounting and advisory firm that specializes in capital markets transactions. Today we have Ted who is here from ProPhase Labs to give the next presentation.Speaker0I'm smiling because a friend of mine from ThinkEquity is in the back. I won't call you out, Frank. Thank you all for joining. Tod ...

Peer-Reviewed Study Conducted in Collaboration with Mayo Clinic Demonstrates 100% Sensitivity and Strong Predictive Power for Esophageal Cancer Progression Early Access Programs and Physician Onboarding Initiatives Expected to Begin in Early 2026 UNIONDALE, NY, Oct. 29, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) today announced that its study, “Assessing Risk of Progression in Barrett’s Esophagus Using a Mass-Spectrometry-Based Proteomic Panel,” has been published online in Clinical and Tra ...

UNIONDALE, NY, Oct. 28, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (the “Company” or “ProPhase”), a next generation biotech, genomics, and consumer products company, today announced that it has engaged RedChip Companies (“RedChip”) to lead its investor relations efforts. “We are entering a transformative phase for ProPhase,” said Ted Karkus, CEO and Chairman of ProPhase Labs. “With the imminent commercialization of our BE-Smart™ esophageal cancer diagnostic, continued expansion of our Nebul ...

UNIONDALE, NY, Oct. 24, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (the “Company” or “ProPhase”), a next generation biotech, genomics, and consumer products company, today announced that it will be participating in the ThinkEquity Conference on October 30, 2025, at the Mandarin Oriental Hotel in New York. The ThinkEquity Conference gathers institutional investors, corporate clients, and other industry professionals to highlight groundbreaking innovations and financial strategies. Ted Karkus ...

Study Acceptance Supports and Provides the Catalyst for Upcoming Commercial Rollout and Revenue-Generating Potential UNIONDALE, NY, Oct. 22, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next generation biotech, genomics and consumer products company, announced today that its pivotal clinical study by Hartley et al. (2025) validating the BE-Smart™ esophageal cancer test has been accepted for publication in Clinical Gastroenterology and Hepatology, the official j ...

ProPhase Labs Inc. (Nasdaq: PRPH), a biotech firm with plans to build a crypto treasury, announced on Sep. 23 that its three COVID-19 testing lab units have filed for reorganization under Chapter 11 bankruptcy in the U.S. Bankruptcy Court for the District of New Jersey. The bankruptcy action is "strictly" limited to the COVID-19 testing lab units which are collectively owed tens of millions of dollars by insurance companies, the statement read. The goal of the bankruptcy filing is to accelerate recovery ...

Core Viewpoint - ProPhase Labs, Inc. has announced that its three COVID-19 testing laboratory subsidiaries have filed for reorganization under Chapter 11 bankruptcy, aiming to recover tens of millions of dollars owed by insurance companies and to ensure long-term viability and growth of the laboratories [1][2][3]. Group 1: Bankruptcy Filing Details - The bankruptcy action is limited to the COVID-19 lab testing units, which are owed tens of millions of dollars by insurance companies [2]. - The company aims to streamline the recovery of funds that it believes are lawfully owed for approved testing services, with many claims previously approved but underpaid by insurance companies [2][3]. - The CEO stated that the Crown Medical Collections group will pursue litigation against insurance companies, estimating potential cash collections of $50 million or more, which could significantly exceed the company's current market capitalization [3]. Group 2: Impact on Company Operations - The bankruptcy process does not affect ProPhase Labs, Inc. as a parent company or its other initiatives, which include the development of a groundbreaking esophageal cancer test [3][4]. - The company continues to advance projects in health technology, including its Nebula Genomics and DNA Complete subsidiaries, which are making progress in genomic and DNA-based testing [3][4]. Group 3: Future Outlook - The company is focused on innovation and growth in health technology, with the bankruptcy filing seen as a necessary step to collect owed funds for reinvestment in ongoing projects [4]. - The exploration of a crypto treasury strategy by the parent company is unrelated to the bankruptcy proceedings involving the lab subsidiaries [4].

Core Insights - ProPhase Labs, Inc. is advancing its crypto treasury strategy following stockholders' approval, aiming to enhance shareholder value without engaging in dilutive financing [2] - The company anticipates generating $50 million in cash from its Crown Medical Collections initiatives and is making progress on its BE-Smart™ Esophageal cancer test [2] - ProPhase Labs is focused on innovation in biotech and genomics, with a mission to revolutionize healthcare through Whole Genome Sequencing and diagnostic development [3] Group 1 - ProPhase Labs has entered into an agreement for potential advisory services and is evaluating options for balance sheet resource allocation, including investments in digital assets [1] - The CEO emphasized the company's significant underlying value, suggesting it could be multiples of the current market capitalization, and stated that the company has no interest in discounted financing [2] - The company is committed to transparency and efforts to preserve and grow shareholder value [2] Group 2 - ProPhase Labs is described as a next-generation biotech and consumer products company, focusing on health and wellness solutions [3] - The company develops and commercializes innovative diagnostic tests, including a potentially life-saving test for early detection of esophageal cancer [3] - ProPhase Labs aims for executional excellence and smart diversification, highlighting the potential for long-term value through its subsidiaries [3]

Core Points - ProPhase Labs stockholders approved all proposals at the Special Meeting on September 9, 2025, with each proposal receiving over 75% support, allowing the company to proceed with strategic initiatives, including increasing authorized shares to 1 billion [1][3] - The Board of Directors was re-elected with over 90% support at the June annual meeting [2] - The increase in authorized shares is intended to provide resources for strategic opportunities, including a potential crypto treasury strategy and the development of current subsidiaries [3] - The company plans to update stockholders on positive developments regarding the Crown Medical Collections initiative, which aims to net up to $50 million in Covid accounts receivables, and the commercialization of the BE-Smart Esophageal Cancer Test [4] Company Overview - ProPhase Labs Inc. is a next-generation biotech, genomics, and consumer products company focused on healthcare innovation through Whole Genome Sequencing solutions and diagnostic development [5] - The company aims to revolutionize healthcare and is committed to executional excellence, smart diversification, and a synergistic approach to its operations [5]

Prophase Labs (PRPH) Conference Summary Company Overview - Prophase Labs is currently focusing on several business verticals, including a significant initiative with Crown Medical Collections, which is projected to generate $50 million in cash collections, potentially exceeding the company's current market cap of $15 million [6][7][19] - The company has a history of successful ventures, including COVID testing, which generated $100 million in annual revenue [8][10] Key Initiatives Crown Medical Collections - The company is pursuing $153 million in collections related to COVID testing, with a conservative estimate of $50 million expected to be collected [14][15] - Legal representation is on a contingency basis, indicating confidence in the collection process [16][17] - Potential securitization of receivables is being explored to secure upfront funding [18] Esophageal Cancer Test (BSmart) - The clinical study results for the esophageal cancer test have been promising, with expectations for publication in a major journal [37][38] - The target market for the test is estimated to be between $7 billion and $14 billion, based on the number of endoscopies performed annually [45] - The test aims to improve diagnostic accuracy for esophageal cancer, which has a high mortality rate due to late diagnosis [41][42] Nebula Genomics - The company has restructured its genomics business, which is now breakeven to profitable after significant overhead reductions [54][60] - The focus is on providing comprehensive DNA analysis and health-related reports, with a strong emphasis on customer retention through subscription models [55][59] Crypto Treasury Strategy - Prophase Labs is developing a crypto treasury strategy, aiming to leverage Bitcoin as a store of value and generate yield without diluting shareholders [69][75] - The strategy involves working with experienced investment bankers and crypto managers to ensure a conservative approach [70][94] - The company plans to raise capital at higher stock prices and invest in Bitcoin, potentially generating significant earnings [81][99] Financial Position and Market Cap - The current market cap of Prophase Labs is approximately $14 million, with a potential net asset value estimated at $100 million or more [85] - The company has faced challenges with high-interest debt but has made significant strides in cleaning up its balance sheet [28][29][64] Management's Vision - The CEO emphasizes a commitment to protecting shareholder value and executing on growth strategies without unnecessary dilution [105][106] - The management team is focused on building value through strategic initiatives and leveraging past successes in the COVID testing space [104][107] Conclusion - Prophase Labs is positioned to capitalize on multiple growth opportunities, including significant cash collections, innovative medical testing, and a strategic entry into the cryptocurrency market, all while maintaining a focus on shareholder value and operational efficiency [19][20][21]